Roivant Sciences Ltd.
ROIV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001635088
In the last 90 days, Roivant Sciences Ltd. insiders filed 0 open-market purchases and 7 sales; 500 institutions reported holding it in 13F filings for Q2 2026, worth $19.7B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Q4 2022 vs. Q3 2022
How the institutions holding Roivant Sciences Ltd. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 78 | 110 | +32 |
| Shares | 370.5M | 411.8M | +41.3M (+11.2%) |
| Value | $1.19B | $3.29B | +$2.10B (+175.8%) |
New holders (42)
Institutions that held Roivant Sciences Ltd. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (10)
Institutions that held Roivant Sciences Ltd. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Balyasny Asset Management LLC | 1,753,210 | $5.64M |
| Chicago Capital, LLC | 938,113 | $3.02M |
| HRT Financial LP | 471,738 | $1.52M |
| Renaissance Technologies LLC | 227,400 | $732.0K |
| Centiva Capital, LP | 155,624 | $501.0K |
| Ergoteles LLC | 37,600 | $121.0K |
| Bayesian Capital Management, LP | 17,525 | $56.0K |
| Simplex Trading, LLC | 15,890 | $51.0K |
| BNP Paribas Arbitrage, SA | 15,200 | $48.9K |
| Group One Trading, L.P. | 11,100 | $36.0K |